



WENDY LAM, PH.D.

Research Analyst
Franklin Equity Group
Franklin Advisers, Inc.
San Mateo, California, United States

Wendy Lam is a research analyst with Franklin Equity Group. She covers biotechnology with a focus on hematology/oncology and orphan diseases.

Dr. Lam joined Franklin Templeton in 2016 and was previously with Oppenheimer & Co as an Executive Director and Senior Analyst covering large-cap biotechnology. She has covered large-cap biotechnology companies since 2013 and began her career as an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley, and Oppenheimer & Co.

Dr. Lam received her Ph.D. in Biology from MIT and holds a B.A. in Molecular & Cell Biology from UC Berkeley.